AstraZeneca Hypertension Drug Wins Nod From EU Regulator

By Adria Calatayud

 

The European Medicines Agency said Friday that its human-medicines committee recommended AstraZeneca's Baxfendy drug for approval to treat insufficiently controlled hypertension.

The nod from the EU drug regulator comes after the Food and Drug Administration gave the green light to the medicine in May. The European Commission, the EU's executive arm, has the final say on the approval of the medicine in the bloc.

AstraZeneca has previously said Baxfendy could generate more than $5 billion in annual revenue at its peak.

 

Write to Adria Calatayud at adria.calatayud@wsj.com

 

(END) Dow Jones Newswires

November 13, 2026 06:55 ET (11:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center